GFI1 (E5J6J) Rabbit Monoclonal Antibody #31929

GFI1 and its homolog GFI1b are transcriptional repressors and important regulators of hematopoiesis (1). GFI1/GFI1b negatively regulate transcription by recruiting chromatin regulatory proteins including CoREST, the histone demethylase LSD1, and HDACs 1 and 2, which associate with the GFI1 proteins via their N-terminal SNAG repression domains (2,3). GFI1 is expressed in hematopoietic stem cells (HSCs), where it is necessary to restrict HSC proliferation and maintain functional integrity (4,5). It is also expressed in common lymphoid and myeloid progenitors, where it plays an essential role in lymphoid and granulo-monocytic differentiation (5,6). Indeed, GFI1 knockout mice show impaired granulocytic differentiation and develop severe neutropenia, causing them to die quickly due to bacterial infection (7,8). In contrast, GFI1b is necessary for erythroid and megakaryocytic development and differentiation, and inactivation of GFI1b in mice leads to embryonic lethality (9). Unsurprisingly, the GFI1 proteins are implicated in multiple blood disorders, and GFI1 specifically is considered to be a predictor and therapeutic target for acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) (10). A GFI1 variant protein caused by a point mutation (S36N) may also confer a disposition to AML and accelerate disease progression (11,12). Interestingly, GFI1 has also been described to be an oncogenic driver for certain subsets of Group 3 medulloblastomas (13,14).